|3 Months Ended
Mar. 31, 2023
3. STOCKHOLDERS’ EQUITY
In February 2023, the Company completed an underwritten registered public offering of 100,000 in gross proceeds from the public offering and $94,766 in net proceeds after deducting the underwriting discount and offering expenses paid by the Company. In addition, the underwriters had a 30-day option to purchase up to an additional shares of common stock from the Company at the public offering price, less the underwriting discounts and commissions. The public offering was made pursuant to our automatic shelf registration statement on Form S-3ASR filed with the SEC on January 6, 2021, and prospectus supplement dated February 8, 2023. Barclays acted as the sole book-running manager for the offering. H.C. Wainwright & Co., Roth Capital Partners and ThinkEquity acted as co-managers for the offering. The underwriters did not exercise their over-allotment option.shares of its common stock at a public offering price of $ per share. The Company received approximately $
During the three months ended March 31, 2023, the Company issued an aggregate of 557,733 shares of common stock pursuant to exercises of warrants to purchase an aggregate of 557,733 shares of common stock for aggregate net proceeds of $835.
During the three months ended March 31, 2023, the Company issued an aggregate of 132. shares of common stock for services to a board member with an issuance date fair value of $
The Company recognized stock-based compensation expense related to common stock, stock options and warrants for the three months ended March 31, 2023 and 2022 of $ and $ , respectively, which is included within compensation expense on the condensed consolidated statements of operations. As of March 31, 2023, there was $ of unrecognized stock-based compensation expense that will be recognized over the weighted average remaining vesting period of years.